Aeglea BioTherapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., Oct. 2, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that, Aeglea's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 2,900,000 shares of common stock of Aeglea to two non-executive employees as equity inducement awards under the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan"). The stock options were approved on October 2, 2023 and were material to each employee's acceptance of employment with Aeglea, in accordance with Nasdaq Listing Rule 5635(c)(4).

Read more at prnewswire.com